Inflammasomes are signalling hubs that assemble in response to cell stress or microbial infection, and provide an activation platform for the zymogen protease, caspase-1. Upon activation, caspase-1 triggers the maturation and secretion of potent pro-inflammatory mediators (interleukin-1beta and -18) and induces cell lysis, culminating in the activation of the immune system and antimicrobial defence. Inflammasome signalling can, however, also drive pathology in a range of human auto-inflammatory, inflammatory, metabolic and neurodegenerative diseases. Here we reveal the mechanisms by which inflammasomes signal, and how a small molecule inflammasome inhibitor can silence pathological inflammasome signalling for therapeutic management of disease.
|Number of pages||1|
|Publication status||Published - 21 Aug 2019|
|Event||48th Annual Scientific Meeting International Society for Experimental Hematology - Brisbane Convention & Exhibition Centre, Brisbane, Australia|
Duration: 22 Aug 2019 → 25 Aug 2019
|Conference||48th Annual Scientific Meeting International Society for Experimental Hematology|
|Period||22/08/2019 → 25/08/2019|